Cardiff Oncology (CRDF) Gets FDA Fast Track for Onvansertib
阅读少于1分钟
The FDA granted Fast Track designation to onvansertib with FOLFIRI/bevacizumab for first-line KRAS- or NRAS-mutated metastatic colorectal cancer. In the Phase 2 trial, the 30 mg regimen had a 72.2% confirmed response rate versus 42.1% with standard care alone.
Material Details
| # | Detail | AI Analyst View |
|---|---|---|
| 1 | FDA grants Fast Track for first-line RAS-mutated mCRC | May facilitate development and review, but does not change approval standards or guarantee approval. |
| 2 | Confirmed response rate: 72.2% vs 42.1% | The 30 mg regimen showed a 30-point improvement over FOLFIRI/bevacizumab alone in the intent-to-treat population. |
| 3 | Median PFS not reached vs approx. 11 months | As of September 28, 2026, median PFS was not reached in the 30 mg arm; combined standard-of-care arms were approximately 11 months. |
Context by AI Analyst
This is a clinical and regulatory milestone for a clinical-stage company advancing onvansertib toward a planned registrational trial. Initiation of that trial and subsequent efficacy and safety data would be needed to establish a larger catalyst.
Based on the original press release from Cardiff Oncology, Inc. distributed by GlobeNewswire.
This is an AI-generated summary and may contain inaccuracies. Summary is based on content distributed by GlobeNewswire. Please verify any important information with the original source. This information is not a recommendation for what you should do personally and does not constitute investment advice.